Lenalidomide is under clinical development by Starton Therapeutics and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lenalidomide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lenalidomide is under development for the treatment of relapsed and refractory multiple myeloma and chronic lymphocytic leukemia (CLL). It is administered through transdermal and subcutaneous route and acts by targeting protein cereblon (CRBN). The drug candidate is developed based on permeation enhanced transdermal technology (PETT) platform.
It was also under development for the treatment of myelodysplastic syndrome and mantle cell lymphoma.
Starton Therapeutics overview
Starton Therapeutics (Starton), is a biotechnology company that discovers and develops drugs for the treatment of hematological malignancies. The company is investigating Star-LLD to treat chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). It is also evaluating STAR-OLZ, to control PARP inhibitor and chemotherapy-induced nausea and vomiting; and STAR-RK against nerve disorders. Starton applies transdermal technology, where an adhesive patch is used to deliver medicine through the skin. The company develops products in the therapeutic areas of hematology and oncology. Starton is headquartered in Paramus, New Jersey, the US.
For a complete picture of Lenalidomide’s drug-specific PTSR and LoA scores, buy the report here.